343 related articles for article (PubMed ID: 9524123)
1. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor.
Migliaccio A; Piccolo D; Castoria G; Di Domenico M; Bilancio A; Lombardi M; Gong W; Beato M; Auricchio F
EMBO J; 1998 Apr; 17(7):2008-18. PubMed ID: 9524123
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells.
Migliaccio A; Di Domenico M; Castoria G; de Falco A; Bontempo P; Nola E; Auricchio F
EMBO J; 1996 Mar; 15(6):1292-300. PubMed ID: 8635462
[TBL] [Abstract][Full Text] [Related]
3. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
4. Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells.
Ballaré C; Uhrig M; Bechtold T; Sancho E; Di Domenico M; Migliaccio A; Auricchio F; Beato M
Mol Cell Biol; 2003 Mar; 23(6):1994-2008. PubMed ID: 12612073
[TBL] [Abstract][Full Text] [Related]
5. Chromatin remodeling and control of cell proliferation by progestins via cross talk of progesterone receptor with the estrogen receptors and kinase signaling pathways.
Vicent GP; Ballaré C; Zaurin R; Saragüeta P; Beato M
Ann N Y Acad Sci; 2006 Nov; 1089():59-72. PubMed ID: 17261755
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
7. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF.
Filardo EJ; Quinn JA; Bland KI; Frackelton AR
Mol Endocrinol; 2000 Oct; 14(10):1649-60. PubMed ID: 11043579
[TBL] [Abstract][Full Text] [Related]
8. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.
Pietras RJ; Arboleda J; Reese DM; Wongvipat N; Pegram MD; Ramos L; Gorman CM; Parker MG; Sliwkowski MX; Slamon DJ
Oncogene; 1995 Jun; 10(12):2435-46. PubMed ID: 7784095
[TBL] [Abstract][Full Text] [Related]
9. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
10. Rapid activation of mitogen-activated protein kinase and p21ras by prolactin and interleukin 2 in rat Nb2 node lymphoma cells.
Rao YP; Buckley DJ; Buckley AR
Cell Growth Differ; 1995 Oct; 6(10):1235-44. PubMed ID: 8845300
[TBL] [Abstract][Full Text] [Related]
11. p130Cas interacts with estrogen receptor alpha and modulates non-genomic estrogen signaling in breast cancer cells.
Cabodi S; Moro L; Baj G; Smeriglio M; Di Stefano P; Gippone S; Surico N; Silengo L; Turco E; Tarone G; Defilippi P
J Cell Sci; 2004 Mar; 117(Pt 8):1603-11. PubMed ID: 15020686
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor, growth factor receptor and protooncogene protein activities and possible signal transduction crosstalk in estrogen dependent and independent breast cancer cell lines.
Mohamood AS; Gyles P; Balan KV; Hollis VW; Eckberg WR; Asseffa A; Han Z; Wyche JH; Anderson WA
J Submicrosc Cytol Pathol; 1997 Jan; 29(1):1-17. PubMed ID: 9066137
[TBL] [Abstract][Full Text] [Related]
13. Progestins reinitiate cell cycle progression in antiestrogen-arrested breast cancer cells through the B-isoform of progesterone receptor.
McGowan EM; Russell AJ; Boonyaratanakornkit V; Saunders DN; Lehrbach GM; Sergio CM; Musgrove EA; Edwards DP; Sutherland RL
Cancer Res; 2007 Sep; 67(18):8942-51. PubMed ID: 17875737
[TBL] [Abstract][Full Text] [Related]
14. Activation of mitogen- and stress-activated kinase 1 is required for proliferation of breast cancer cells in response to estrogens or progestins.
Reyes D; Ballaré C; Castellano G; Soronellas D; Bagó JR; Blanco J; Beato M
Oncogene; 2014 Mar; 33(12):1570-80. PubMed ID: 23604116
[TBL] [Abstract][Full Text] [Related]
15. Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the ras signaling pathway.
Clark JW; Santos-Moore A; Stevenson LE; Frackelton AR
Int J Cancer; 1996 Jan; 65(2):186-91. PubMed ID: 8567115
[TBL] [Abstract][Full Text] [Related]
16. Progestin activation of nongenomic pathways via cross talk of progesterone receptor with estrogen receptor beta induces proliferation of endometrial stromal cells.
Vallejo G; Ballaré C; Barañao JL; Beato M; Saragüeta P
Mol Endocrinol; 2005 Dec; 19(12):3023-37. PubMed ID: 16020483
[TBL] [Abstract][Full Text] [Related]
17. The cooked food derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine is a potent oestrogen: a mechanistic basis for its tissue-specific carcinogenicity.
Lauber SN; Ali S; Gooderham NJ
Carcinogenesis; 2004 Dec; 25(12):2509-17. PubMed ID: 15319301
[TBL] [Abstract][Full Text] [Related]
18. Progestin-dependent induction of vascular endothelial growth factor in human breast cancer cells: preferential regulation by progesterone receptor B.
Wu J; Richer J; Horwitz KB; Hyder SM
Cancer Res; 2004 Mar; 64(6):2238-44. PubMed ID: 15026368
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade.
Wong CW; McNally C; Nickbarg E; Komm BS; Cheskis BJ
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14783-8. PubMed ID: 12415108
[TBL] [Abstract][Full Text] [Related]
20. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I.
Martin MB; Franke TF; Stoica GE; Chambon P; Katzenellenbogen BS; Stoica BA; McLemore MS; Olivo SE; Stoica A
Endocrinology; 2000 Dec; 141(12):4503-11. PubMed ID: 11108261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
